Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting

Journal of Laryngology and Otology

Volumn 126, Issue 6, 2012, Pages 548-551

  Harris, T ^a,b   Peer, S ^b   Fagan, J J ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Aminoglycosides; Audiology; Cisplatin; Developing World; HAART; Highly Active Antiretroviral Therapy; Iphone; Mobile Devices; Ototoxicity; Screening Programs

Indexed keywords

AMINOGLYCOSIDE; ANTIRETROVIRUS AGENT; CISPLATIN;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL THERAPY; AUDIOLOGY; CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DRUG INDUCED DISEASE; HEARING IMPAIRMENT; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NEOPLASM; NONHUMAN; PATIENT MONITORING; REVIEW; SOUTH AFRICA;

AFRICA SOUTH OF THE SAHARA; AMINOGLYCOSIDES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; AUDIOLOGY; AUDIOMETRY, PURE-TONE; CELLULAR PHONE; DEVELOPING COUNTRIES; DRUG SYNERGISM; HEARING LOSS; HIV INFECTIONS; HUMANS; MASS SCREENING; MEDICALLY UNDERSERVED AREA; NEOPLASMS; TUBERCULOSIS;

EID: 84861819119     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215112000357     Document Type: Review

References (33)

1. Olusanya BO, Newton VE. Promoting a global health agenda for permanent childhood hearing impairment. Journal of Community Ear and Hearing Health 2007;4:5-27
2. World Health Organization. Report of an Informal Consultation on Strategies for Prevention of Hearing Impairment from Ototoxic Drugs. Geneva: World Health Organization, 1994
3. UNAIDS, Global Report. In: http://www.unaids.org/en/KnowledgeCentre/ HIVData/EpiUpdate/EpiUpdArchive/2007 [30 Jul 2010]
4. Birchall MA, Wight RG, French PD, Cockbain Z, Smith SJ. Auditory function in patients infected with the human immunodeficiency virus. Clin Otolaryngol 1992;17:117-21
5. Lalwani AK, Sooy CD. Otologic and neurotologic manifestations of acquired immunodeficiency syndrome. Otolaryngol Clin North Am 1992;25:1183-97
6. Soucek S, Michaels L. The ear in the acquired immunodeficiency syndrome: II. Clinical and audiologic investigation. Am J Otol 1996;17:35-9
7. Fagan JJ, Jacobs M. Survey of ENT services in Africa: need for a comprehensive intervention. Global Health Action 2009;Mar 19:2
8. Saunders JE, Greinwald JH, Vaz S, Guo Y. Aminoglycoside ototoxicity in Nicaraguan children: patient risk factors and mitochondrial DNA results. Otolaryngol Head Neck Surg 2009;140: 103-7
9. World Health Organization. Global Tuberculosis Control 2008: Surveillance, Planning, Financing. Geneva: WHO Report, 2008
10. World Health Organization. Multidrug and extensively drug resistant TB (M/XDR-TB). 2010 Report on Surveillance and Response. Geneva: World Health Organization, 2010
11. Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. Drug Discov Today 2005;10:1313-21
12. Bokemeyer C, Berger CC, Hartmann JT, Kollmansberger C, Schmoll HJ, Kuczyck MA et al. Analysis of risk factors for cisplatin- induced ototoxicity in patients with testicular cancer. Br J Cancer 1998;77:1355-62
13. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2006;226:157-67
14. Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002;52:599-605
15. Chandrasekhar SS, Connelly PE, Brahmbhatt SS, Shah CS, Kloser PC, Baredes S. Otologic and audiologic evaluation of human immunodeficiency virus-infected patients. Am J Otolaryngol 2000;21:1-9
16. Michaels L, Soucek S, Liang J. The ear in the acquired immunodeficiency syndrome: I. Temporal bone histopathologic study. Am J Otol 1994;15:515-22
17. Meynard JL, el Amrani M, Meyohas MC, Fligny I, Gozian J, Rozenbaum W et al. Two cases of cytomegalovirus infection revealed by hearing loss in HIV-infected patients. Biomed Pharmacother 1997;51:461-3
18. Little JP, Gardner G, Acker JD, Land MA. Otosyphilis in a patient with human immunodeficiency virus: internal auditory canal gumma. Otolaryngol Head Neck Surg 1995;112:488-92
19. Grimaldi LME, Luzi L, Martino GV, Furlan R, Nemni A, Antonelli N et al. Bilateral eighth cranial nerve neuropathy in human immuodeficiency virus infection. J Neurol 1993;240: 363-6
20. McArthur JC. Neurological manifestations of AIDS. Medicine 1987;66:407-37
21. Moore JM, James IR, Nolan D, Upton RP, McKinnon EJ, Mallal SA. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:717-23
22. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviraltherapy- related lipodystrophy. Lancet 1999;354:1112-15
23. Anuurad E, Semrad A, Berglund L. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord 2009;7:401-9
24. Marra CM, Wechkin HA, Longstreth WT, Rees T, Syapin CL, Gates GA. Hearing loss and antiretroviral therapy in patients infected with HIV-1. Arch Neurol 1997;54:407-10
25. Simdon J, Watters D, Bartlett S, Connick E. Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature. Clin Infect Dis 2001;32:1623-7
26. McNaghten AD, Wan PT, Dworkin MS. Correspondence: prevalence of hearing loss in a cohort of HIV-infected patients. Arch Otolaryngol Head Neck Surg 2001;127:1516-18
27. Khoza-Shangase K. Highly active antiretroviral therapy: does it sound toxic? J Pharm Bioallied Sci 2011;3:142-53
28. Bektas D, Martin GK, Stagner BB, Lonsbury-Martin BL. Noiseinduced hearing loss in mice treated with antiretroviral drugs. Hear Res 2008;239:69-78
29. Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011;20: 2551-9
30. Fausti SA, Helt WJ, Gordon JS, Reavis KM, Phillips DS, Konrad-Martin D. Audiologic monitoring for ototoxicity and patient management. In: Campbell KC, ed. Pharmacology and Ototoxicity for Audiologists, 1st edn. New York: Thomson Delmar Learning, 2006;230-48
31. Sturdy A, Goodman A, José RJ, Loyse A, O'Donoghue M, Kon OM et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011;66:1815-20
32. Swart S. Draft Report. Modernisation of Audiology Services. Cape Town: Western Cape Department of Health, 2010
33. DOTS-Plus for Standardised Management of Multidrugresistant Tuberculosis in South Africa - Policy Guidelines. In: http://www.sahealthinfo.org/tb/ mdrtbguidelines.pdf [17 November 2011]